dr. pal on the safety profile of cabozantinib/atezolizumab in advanced rcc
Published 4 years ago • 435 plays • Length 0:51Download video MP4
Download video MP3
Similar videos
-
0:51
dr. pal on the rationale for adding cabozantinib to atezolizumab in prostate cancer
-
1:19
dr. agarwal on the safety of cabozantinib/atezolizumab in mcrpc
-
1:05
dr. pal on potential tivozanib-based combinations in rcc
-
0:48
dr. pal on preoperative immunotherapy in patients with rcc
-
1:06
dr. pal on crispr-based technology in rcc
-
0:48
dr. pal discusses the role of pd-l1 in metastatic rcc
-
1:32
dr. mcgregor on the future of cabozantinib in rcc
-
0:43
dr. pal on sequencing nivolumab in rcc
-
10:25
for hcps: learn about the cabometyx® (cabozantinib) mechanism of action
-
1:42
q-gen cell therapeutics developing cell therapy for cancer with alloplex
-
1:55:41
pilocarpine eye drops for presbyopia
-
0:41
dr. pal on molecular signatures in renal cell carcinoma
-
0:52
dr. choueiri on the role of cabozantinib in rcc
-
1:20
promising results of cabozantinib plus nivolumab in non-clear cell rcc
-
0:52
dr. pal on the rationale for the tivo-3 trial with tivozanib in advanced rcc
-
1:06
dr. toni choueiri on nivolumab and cabozantinib becoming first-line therapies in rcc
-
5:56
the rationale for cabozantinib in advanced rcc
-
3:53
cabozantinib in combination with immunotherapy for advanced renal cell carcinoma
-
4:15
contact-303: primary pfs analysis of atezolizumab and cabozantinib in ccrcc
-
1:13
dr. agarwal on data with cabozantinib/atezolizumab in mcrpc
-
12:41
cabozantinib in combination with atezolizumab in patients with mcrpc
-
2:02
dr. jorge garcia on meteor trial for rcc